about
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacyTh1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85AA Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsComparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal deliveryNon-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.Characterization of the effect of LPS on dendritic cell subset discrimination in spleenSpleen as a site for hematopoiesis of a distinct antigen presenting cell type.Dendritic cells as immune regulators: the mouse model.The B subunit of Escherichia coli heat-labile toxin alters the development and antigen-presenting capacity of dendritic cellsHelminth-induced arginase-1 exacerbates lung inflammation and disease severity in tuberculosisImprovement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85AIdentification of a novel antigen cross-presenting cell type in spleenA novel multivalent tuberculosis vaccine confers protection in a mouse model of tuberculosis.Investigation into the prevalence of a novel dendritic-like cell subset in vivo.Novel vaccine approaches for protection against intracellular pathogens.Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.Splenic stromal niches support hematopoiesis of dendritic-like cells from precursors in bone marrow and spleenSpleen stroma maintains progenitors and supports long-term hematopoiesis
P50
Q28354371-D0C85778-D95B-4BC9-BA45-E2037AC708C5Q28740954-0C797F00-23DF-4C74-857F-90B51CD0C1E4Q28742450-BE0DA34B-6DAF-4C48-A730-A3E076CFB229Q33603206-5E103059-0B7F-484E-90B7-E141565BD4CAQ33791961-4F558942-CDC3-49BF-AEBC-3DCF743FBDADQ34259027-288CC56E-5CF4-4826-A05A-A55C9096C1B8Q34336900-A76381BC-7300-4151-952E-0EE1942DB679Q35608763-00BB965D-FB85-4B5D-9C48-729221A65365Q35862456-06411C7E-359C-4D61-9E7F-72E09E34A170Q35995130-36723145-B99D-44C7-82FE-35C5FA5B77D1Q36335912-32351996-C038-4EA2-8073-3FF3E5E16ACDQ36369598-F9ED7C10-C041-44C4-A72C-F6A64E128B57Q37294081-4104669A-D170-4573-8C39-7090BC5BEB9AQ37375963-B6F1D975-78F8-4048-82AD-E4574B91D9DFQ37557545-D946B11E-E8BD-4DA5-97A3-66CB333BD81AQ38194389-860D8B38-424E-4532-8268-EAB52BB3E850Q41517191-7D13224C-AC3B-44EC-B5F1-7134ECAFBF0BQ84090067-63AD4991-9BD2-418E-BC44-5AE173AB2B2CQ87709655-D360C6D4-8070-4099-9794-5ECCA9466F9F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
K L Griffiths
@en
K L Griffiths
@nl
type
label
K L Griffiths
@en
K L Griffiths
@nl
prefLabel
K L Griffiths
@en
K L Griffiths
@nl
P31
P496
0000-0002-6008-2955